Fluoxetine was safe and effective for body dysmorphic disorder


QUESTION: In patients with body dysmorphic disorder (BDD), is fluoxetine hydrochloride more effective than placebo?

Design
Randomised (allocation concealed*), blinded (clinicians, patients, and outcome assessors*), placebo controlled trial with 12 weeks of follow up.

Setting
An academic centre in Providence, Rhode Island, USA.

Patients
74 patients who had DSM-IV confirmed BDD with or without a delusional disorder for ≥ 6 months, were 18–65 years of age, scored ≥ 24 on the Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder (BDD-YBOCS), and scored at least moderate on the Clinical Global Impression scale for BDD (BDD-CGI). Exclusion criteria included psychotic disorder not attributable to delusional BDD, bipolar disorder, alcohol or substance abuse in the previous 6 months, body image concerns better accounted for by an eating disorder, suicide attempt or ideation, recent use of certain psychiatric drugs or psychotherapy, and potential for pregnancy. 67 patients (mean age 32 y, 69% women) were randomised and 59 (88%) completed the trial.

Intervention
Patients completed a 1 week placebo run in period and were allocated to fluoxetine, 20 mg/day, (n=33) or placebo (n=33) for 2 weeks. The dose was increased by 20 mg/day every 10 days to a maximum of 80 mg/day.

Main outcome measures
Change on the BDD-YBOCS (clinical response was a ≥ 30% decrease in total score). Secondary outcomes were improvement on the BDD-CGI, depressive symptoms, psychosocial functioning, and adverse effects.

Main results
Analysis was by intention to treat. 27 patients (40%) were delusional at baseline. Improvement on the BDD-YBOCS was greater in the fluoxetine group than the placebo group; differences started at week 8 (p=0.01) and continued through to week 12 (p < 0.001). Clinical response was greater in the fluoxetine group than the placebo group (p=0.003) (table). More patients who received fluoxetine were much or very much improved (p=0.02) and patient rated (p=0.02) BDD-CGI. Functional impairment was also more improved with fluoxetine (p<0.001), as were depressive symptoms (p=0.01). Patients who were delusional at baseline were as likely as non-delusional patients to respond to fluoxetine. Drowsiness and stomach or abdominal discomfort were the only adverse effects that occurred more frequently with fluoxetine (p ≤ 0.01).

Conclusion
In delusional and non-delusional patients with body dysmorphic disorder, fluoxetine hydrochloride was more effective than placebo.

*See glossary.

Fluoxetine v placebo for body dysmorphic disorder at 12 weeks*

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Fluoxetine</th>
<th>Placebo</th>
<th>RBI (95% CI)</th>
<th>NNT (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥30% decrease on BDD-YBOCS total score</td>
<td>53%</td>
<td>18%</td>
<td>191% (40 to 548)</td>
<td>3 (2 to 9)</td>
</tr>
</tbody>
</table>

*BDDB-YBOCS = Yale-Brown Obsessive Compulsive Scale Modified for Body Dysmorphic Disorder. Other abbreviations defined in glossary; RBI, NNT, and CI calculated from data in article.

COMMENTARY
BDD is a chronic and under recognised condition. Patients often present to dermatology and cosmetic surgery clinics rather than to psychiatry clinics. Untreated BDD and BDD treated with a non-psychiatric medical intervention have a poor outcome. BDD has been considered a part of the obsessive compulsive disorder (OCD) spectrum, but also has high rates of comorbid depression. A crossover trial showed better outcomes with serotonergic reuptake inhibition. The study by Phillips et al is timely because it is the only randomised, placebo controlled trial of a serotonergic reuptake inhibitor for BDD.

In addition to screening for placebo responders, the study design also balanced the groups for OCD, depression, and delusional ideation. Although the outcome assessor was blind to adverse events, the individual was able to guess the patient allocation to treatment or placebo groups correctly in 60% of the cases.

The presence of depressive and obsessive symptoms did not predict the outcome, although change in depression scores correlated with improvement. Patients with delusional ideation responded to fluoxetine but not to placebo. However, the delusions themselves did not respond to treatment. Future trials may need to assess whether antipsychotic augmentation could alter delusional thinking. A role may exist for augmentation with cognitive behaviour therapy and other pharmacological agents to enhance response. Interestingly, open label fluoxetine treatment of placebo non-responders yielded a 24% response rate. Insufficient information exists to conclude what the findings of the study would be if treatment dropouts were analysed as treatment failures.

This pivotal study provides a better alternative to expensive and ineffective medical or surgical interventions in patients with BDD. However, these results may apply only to specialist liaison settings because the general psychiatric practitioner may not encounter the diagnosis frequently enough.

In a national health service set-up, as in the UK, most of cosmetic surgery practice is based in the less regulated private sector often with self referred patients. This may make detection and appropriate treatment of BDD more difficult.

Sanjay Rao, MD, MRCPsych
Royal Victoria Infirmary
Newcastle-upon-Tyne, UK


Sources of funding:
National Institute of Mental Health.
Fluoxetine and placebo supplied by Eli Lilly.
For correspondence: Dr K A Phillips, Butler Hospital, Providence, RI USA. katharine_phillips@brown.edu